| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.94 [0.80, 1.11] | | < 1 | | 0% | 1 study (1/-) | 76.8 % | NA | not evaluable | | crucial | - |
| progression or deaths (PFS) | 1.05 [0.72, 1.53] | | < 1 | | 0% | 1 study (1/-) | 40.0 % | NA | not evaluable | | important | - |
| objective responses (ORR) | 0.87 [0.55, 1.37] | | > 1 | | 0% | 1 study (1/-) | 27.3 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.51 [0.27, 0.96] | | < 1 | | 0% | 1 study (1/-) | 98.2 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 1.02 [0.76, 1.37] | | < 1 | | 0% | 1 study (1/-) | 44.6 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 2.19 [1.17, 4.11] | | < 1 | | 0% | 1 study (1/-) | 0.7 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.43 [0.97, 2.10] | | < 1 | | 0% | 1 study (1/-) | 3.5 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 2.14 [1.32, 3.47] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 1.93 [1.22, 3.04] | | < 1 | | 0% | 1 study (1/-) | 0.2 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 1.52 [1.03, 2.24] | | < 1 | | 0% | 1 study (1/-) | 1.7 % | NA | not evaluable | | non important | - |
| STRAE (grade 3-4) | 1.43 [0.92, 2.21] | | < 1 | | 0% | 1 study (1/-) | 5.6 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.31 [0.22, 0.44] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 0.55 [0.39, 0.77] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 1.91 [0.47, 7.71] | | < 1 | | 0% | 1 study (1/-) | 18.2 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (any grade) | 1.47 [0.92, 2.35] | | < 1 | | 0% | 1 study (1/-) | 5.3 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 2.95 [1.51, 5.78] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 5.73 [0.29, 114.82] | | < 1 | | 0% | 1 study (1/-) | 13.0 % | NA | not evaluable | | non important | - |
| Alopecia TRAE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.01 [0.00, 0.19] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.06 [0.00, 1.01] | | < 1 | | 0% | 1 study (1/-) | 97.3 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 13.52 [0.76, 239.13] | | < 1 | | 0% | 1 study (1/-) | 3.9 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 0.47 [0.02, 14.16] | | < 1 | | 0% | 1 study (1/-) | 66.4 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.95 [0.24, 3.82] | | < 1 | | 0% | 1 study (1/-) | 53.0 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 1.90 [0.06, 56.82] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 4.35 [0.93, 20.28] | | < 1 | | 0% | 1 study (1/-) | 3.1 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 1.09 [0.39, 3.03] | | < 1 | | 0% | 1 study (1/-) | 43.7 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 13.52 [0.76, 239.13] | | < 1 | | 0% | 1 study (1/-) | 3.9 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.90 [0.06, 56.82] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 1.90 [0.06, 56.82] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 5.73 [0.29, 114.82] | | < 1 | | 0% | 1 study (1/-) | 13.0 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.16 [0.02, 1.30] | | < 1 | | 0% | 1 study (1/-) | 95.6 % | NA | not evaluable | | non important | - |
| Nephritis TRAE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.01 [0.00, 0.20] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 7.74 [0.96, 62.17] | | < 1 | | 0% | 1 study (1/-) | 2.8 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 0.95 [0.06, 15.23] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.03 [0.00, 0.42] | | < 1 | | 0% | 1 study (1/-) | 99.4 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.07 [0.00, 1.18] | | < 1 | | 0% | 1 study (1/-) | 96.6 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Alopecia AE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 0.12 [0.05, 0.28] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.86 [0.36, 2.05] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
| Back pain AE (grade 3-4) | 0.63 [0.10, 3.80] | | < 1 | | 0% | 1 study (1/-) | 69.2 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 1.90 [0.17, 21.07] | | < 1 | | 0% | 1 study (1/-) | 30.1 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 1.43 [0.40, 5.11] | | < 1 | | 0% | 1 study (1/-) | 29.1 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 2.12 [0.73, 6.17] | | < 1 | | 0% | 1 study (1/-) | 8.4 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 1.11 [0.37, 3.33] | | < 1 | | 0% | 1 study (1/-) | 42.7 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 1.31 [0.52, 3.31] | | < 1 | | 0% | 1 study (1/-) | 28.1 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.63 [0.18, 2.25] | | < 1 | | 0% | 1 study (1/-) | 76.2 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 0.01 [0.00, 0.19] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 0.95 [0.06, 15.23] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.03 [0.00, 0.42] | | < 1 | | 0% | 1 study (1/-) | 99.4 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.13 [0.02, 1.09] | | < 1 | | 0% | 1 study (1/-) | 96.9 % | NA | not evaluable | | non important | - |
| Weight decreased AE (grade 3-4) | 2.86 [0.30, 27.64] | | < 1 | | 0% | 1 study (1/-) | 18.3 % | NA | not evaluable | | non important | - |
